Fibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We here describe insights underpinning the impact of mutations on FGFR1 and FGFR3 kinase activity and drug efficacy, using a combination of computational calculations and experimental approaches including cellular studies, X-ray crys- tallography and biophysical and biochemical measurements. Our findings reveal that some of the tested compounds, in particular TKI258, could provide therapeutic opportunity not only for patients with primary alter- ations in FGFR but also for acquired resistance due to the gatekeeper mutation. The accuracy of the computational methodologies applied here shows a potential for their wider application in studies of drug bindi...
Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Recepto...
The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for the stem ...
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) can be drivers of canc...
Fibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We here des...
AbstractFibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We ...
Fibroblast growth factor receptors (FGFRs) are recurrently altered by single nucleotide variants (SN...
Genetic alterations such as mutations in the Fibroblast Growth Factor Receptors (FGFRs) family play ...
Human fibroblast growth factor receptors (FGFRs) 1–4 are a family of receptor tyrosine kinases that ...
Frequent genetic alterations discovered in FGFRs and evidence implicating some as drivers in diverse...
<p>Tyrosine kinase inhibitors (TKI)-resistant mutation in epidermal growth factor receptor’s (EGFR) ...
AbstractThe four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth Factor Rece...
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) can be drivers of canc...
Receptor tyrosine kinase (RTK) signalling is frequently deregulated in cancers, developmental syndro...
Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a pathway c...
International audienceThe fundamental oncology-related research is required for a deeper understandi...
Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Recepto...
The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for the stem ...
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) can be drivers of canc...
Fibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We here des...
AbstractFibroblast growth factor receptors (FGFRs) are recognized therapeutic targets in cancer. We ...
Fibroblast growth factor receptors (FGFRs) are recurrently altered by single nucleotide variants (SN...
Genetic alterations such as mutations in the Fibroblast Growth Factor Receptors (FGFRs) family play ...
Human fibroblast growth factor receptors (FGFRs) 1–4 are a family of receptor tyrosine kinases that ...
Frequent genetic alterations discovered in FGFRs and evidence implicating some as drivers in diverse...
<p>Tyrosine kinase inhibitors (TKI)-resistant mutation in epidermal growth factor receptor’s (EGFR) ...
AbstractThe four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth Factor Rece...
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) can be drivers of canc...
Receptor tyrosine kinase (RTK) signalling is frequently deregulated in cancers, developmental syndro...
Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a pathway c...
International audienceThe fundamental oncology-related research is required for a deeper understandi...
Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Recepto...
The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for the stem ...
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) can be drivers of canc...